Evaluation of pomalidomide in combination with high dose dexamethasone and oral cyclophosphamide in patients with relapsed and refractory myeloma
ID Number 12-1128Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
In February 2013, the Food and Drug Administration approved the use of pomalidomide (pomalyst) for people with multiple myeloma who had at least 2 prior therapies including lenalidomide and bortezomib with disease progression during or within 60 days of their last therapy.
The main purpose of this study is to see whether pomalidomide can help people with myeloma when used together with FDA approved drugs dexamethasone and cyclophosphamide. Researchers also want to find out if pomalidomide is safe and tolerable in combination with these other drugs.
To be able to participate in this research study a person must have been diagnosed with relapsed and refractory multiple myeloma.
Recruiting Patients: Yes